AZN
Price
$65.36
Change
+$0.92 (+1.43%)
Updated
Dec 20, 04:59 PM (EDT)
47 days until earnings call
GSK
Price
$33.60
Change
+$0.17 (+0.51%)
Updated
Dec 20, 04:59 PM (EDT)
46 days until earnings call
Ad is loading...

AZN vs GSK

Header iconAZN vs GSK Comparison
Open Charts AZN vs GSKBanner chart's image
AstraZeneca
Price$65.36
Change+$0.92 (+1.43%)
Volume$78.67K
CapitalizationN/A
GSK
Price$33.60
Change+$0.17 (+0.51%)
Volume$65.17K
CapitalizationN/A
AZN vs GSK Comparison Chart
Loading...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AZN vs. GSK commentary
Dec 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Hold and GSK is a Hold.

COMPARISON
Comparison
Dec 22, 2024
Stock price -- (AZN: $65.36 vs. GSK: $33.60)
Brand notoriety: AZN: Notable vs. GSK: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZN: 142% vs. GSK: 114%
Market capitalization -- AZN: $208.98B vs. GSK: $88.13B
AZN [@Pharmaceuticals: Major] is valued at $208.98B. GSK’s [@Pharmaceuticals: Major] market capitalization is $88.13B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZN’s FA Score shows that 1 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).

  • AZN’s FA Score: 1 green, 4 red.
  • GSK’s FA Score: 2 green, 3 red.
According to our system of comparison, GSK is a better buy in the long-term than AZN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZN’s TA Score shows that 5 TA indicator(s) are bullish while GSK’s TA Score has 3 bullish TA indicator(s).

  • AZN’s TA Score: 5 bullish, 4 bearish.
  • GSK’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AZN is a better buy in the short-term than GSK.

Price Growth

AZN (@Pharmaceuticals: Major) experienced а -1.83% price change this week, while GSK (@Pharmaceuticals: Major) price change was -1.03% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.62%. For the same industry, the average monthly price growth was -3.07%, and the average quarterly price growth was -2.90%.

Reported Earning Dates

AZN is expected to report earnings on Feb 06, 2025.

GSK is expected to report earnings on Feb 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.62% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AZN($209B) has a higher market cap than GSK($88.1B). AZN has higher P/E ratio than GSK: AZN (35.30) vs GSK (14.01). AZN YTD gains are higher at: -0.858 vs. GSK (-5.756). AZN has higher annual earnings (EBITDA): 13.4B vs. GSK (9.08B). AZN has more cash in the bank: 5.86B vs. GSK (4.99B). GSK has less debt than AZN: GSK (18B) vs AZN (28.6B). AZN has higher revenues than GSK: AZN (45.8B) vs GSK (30.3B).
AZNGSKAZN / GSK
Capitalization209B88.1B237%
EBITDA13.4B9.08B148%
Gain YTD-0.858-5.75615%
P/E Ratio35.3014.01252%
Revenue45.8B30.3B151%
Total Cash5.86B4.99B117%
Total Debt28.6B18B159%
FUNDAMENTALS RATINGS
AZN vs GSK: Fundamental Ratings
AZN
GSK
OUTLOOK RATING
1..100
7774
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
7
Undervalued
PROFIT vs RISK RATING
1..100
35100
SMR RATING
1..100
5249
PRICE GROWTH RATING
1..100
6174
P/E GROWTH RATING
1..100
727
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (7) in the Pharmaceuticals Major industry is in the same range as AZN (23). This means that GSK’s stock grew similarly to AZN’s over the last 12 months.

AZN's Profit vs Risk Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (100). This means that AZN’s stock grew somewhat faster than GSK’s over the last 12 months.

GSK's SMR Rating (49) in the Pharmaceuticals Major industry is in the same range as AZN (52). This means that GSK’s stock grew similarly to AZN’s over the last 12 months.

AZN's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as GSK (74). This means that AZN’s stock grew similarly to GSK’s over the last 12 months.

GSK's P/E Growth Rating (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZN (72). This means that GSK’s stock grew somewhat faster than AZN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNGSK
RSI
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
51%
Momentum
ODDS (%)
Bearish Trend 2 days ago
51%
Bearish Trend 2 days ago
47%
MACD
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
42%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
47%
Bearish Trend 2 days ago
52%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 2 days ago
47%
Advances
ODDS (%)
Bullish Trend 13 days ago
54%
Bullish Trend 13 days ago
51%
Declines
ODDS (%)
Bearish Trend 3 days ago
46%
Bearish Trend 3 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
52%
Aroon
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
48%
View a ticker or compare two or three
Ad is loading...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PHR25.161.32
+5.54%
Phreesia
JOB0.230.01
+5.12%
GEE Group
VZLA1.770.06
+3.51%
Vizsla Silver Corp
IQV197.275.75
+3.00%
IQVIA Holdings
EEFT103.670.57
+0.55%
Euronet Worldwide

AZN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AZN has been loosely correlated with NVS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZN
1D Price
Change %
AZN100%
+1.43%
NVS - AZN
50%
Loosely correlated
+0.35%
AZNCF - AZN
48%
Loosely correlated
+3.67%
PFE - AZN
47%
Loosely correlated
+2.29%
SNY - AZN
38%
Loosely correlated
+0.51%
MRK - AZN
34%
Loosely correlated
-1.48%
More

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
+0.51%
NVS - GSK
39%
Loosely correlated
+0.35%
GLAXF - GSK
36%
Loosely correlated
-1.55%
PFE - GSK
35%
Loosely correlated
+2.29%
AZN - GSK
34%
Loosely correlated
+1.43%
JNJ - GSK
33%
Poorly correlated
+0.62%
More